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Abstract
The intercellular communication mediated by extracellular vesicles (EVs) has gained 
international interest during the last decade. Interfering with the mechanisms regu‐
lating this cellular process might find application particularly in oncology where can‐
cer cell‐derived EVs play a role in tumour microenvironment transformation. Although 
several mechanisms were ascribed to explain the internalization of EVs, little is our 
knowledge about the fate of their cargos, which are crucial to mediate their function. 
We recently demonstrated a new intracellular pathway in which a fraction of endo‐
cytosed EV‐associated proteins is transported into the nucleoplasm of the host cell 
via a subpopulation of late endosomes penetrating into the nucleoplasmic reticulum. 
Silencing tetraspanin CD9 both in EVs and recipient cells strongly decreased the en‐
docytosis of EVs and abolished the nuclear transfer of their cargos. Here, we investi‐
gated whether monovalent Fab fragments derived from 5H9 anti‐CD9 monoclonal 
antibody (referred hereafter as CD9 Fab) interfered with these cellular processes. To 
monitor the intracellular transport of proteins, we used fluorescent EVs containing 
CD9‐green fluorescent protein fusion protein and various melanoma cell lines and 
bone marrow‐derived mesenchymal stromal cells as recipient cells. Interestingly, 
CD9 Fab considerably reduced EV uptake and the nuclear transfer of their proteins 
in all examined cells. In contrast, the divalent CD9 antibody stimulated both events. 
By impeding intercellular communication in the tumour microenvironment, CD9 Fab‐
mediated inhibition of EV uptake, combined with direct targeting of cancerous cells 
could lead to the development of novel anti‐melanoma therapeutic strategies.
K E Y W O R D S
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1  | INTRODUC TION
Growing evidence indicate that intercellular communication in 
multicellular organisms is mediated not only by direct cell‐cell 
contact or soluble molecules, but also by extracellular vesicles 
(EVs), ie lipid bilayer‐enclosed nanobiological units actively re‐
leased from all cell types.1,2 In contrast to soluble signalling mol‐
ecules, bioactive compounds associated with EVs (eg, proteins, 
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nucleic acids such as non‐coding RNA [including microRNA], 
mRNA and genomic DNA) are protected from degradation.3,4 EVs 
are found in internal and external bodily fluids and act as mediators 
of long‐distance transfer of biological information. Physiological 
and pathological conditions determine the nature of EVs released 
by the producing cells as well as the abundance of their bioactive 
cargo molecules.5 Under physiological states, EVs can play import‐
ant roles during embryonic development and afterward in the ho‐
moeostasis of various organ systems (reviewed in Ref.6). In cancer, 
they could promote pro‐angiogenic events and alter the surround‐
ing cellular components as well as extracellular matrix to develop 
the pre‐metastatic niche.7,8 With regard to clinical purposes, EVs 
attract additional interest because their production is deregulated 
in human diseases, notably in cancer; hence, their cargo molecules 
can be monitored as biofluid‐associated markers.9,10 Furthermore, 
EVs can be engineered for the selective therapeutic delivery of 
biomacromolecules.6,11
Two major general pathways were ascribed to explain the 
biogenesis and release of EVs by donor cells as exosomes or ec‐
tosomes.12 The first class of EVs is derived from the internal intra‐
luminal vesicles of multivesicular bodies (MVBs) that are formed 
by the inward budding of the endosomal membrane during the 
maturation of MVBs. Upon fusion with the plasma membrane, 
MVBs release them outside the cell. The diameter of exosomes 
varies from 30 to 120 nm. Outward budding and fission of plasma 
membrane generate the second class of EV. Thus, ectosomes are 
typically larger than exosomes and their diameter varies from 
100 nm to 1 μm. We have previously shown that ectosomes can 
bud from microvilli and/or cilia.13,14 Once released into the ex‐
tracellular milieu, the uptake of EVs by recipient cells can be ac‐
complished by several molecular mechanisms of internalization, 
which are not mutually exclusive,15‐18 such as clathrin‐mediated 
endocytosis17 or lipid raft‐dependent endocytosis.19 In spite of 
this knowledge, fundamental questions remain about the fate of 
endocytosed EVs particularly their biological cargo, which is cru‐
cial for their function.20
Our groups are studying EVs released by stem cells and cancer‐
ous cells, notably melanoma cells. We have extensively character‐
ized those secreted by metastatic FEMX‐I cells. Electron microscopy 
examination has revealed the presence of a mixture of small and 
large EVs, suggesting that exosomes and ectosomes are simulta‐
neously produced.21 The proteomic analysis of EVs, particularly 
those harbouring the stem (cancer stem) cell marker CD133,22 has 
defined their contents. They are particularly rich in tetraspanin pro‐
teins (CD9, CD63 and CD81) and in pro‐metastatic proteins, notably 
CD44, MAPK4K, ADAM10 and Annexin A2. Importin β1, a protein 
mediating nuclear transportation of cytoplasmic proteins through 
the nuclear pore complex, was also found therein. By monitoring the 
internalization of melanoma‐derived EVs and the intracellular routes 
of their content, particularly CD9 (see below), we discovered that 
EV‐associated proteins are transported into the nucleus of the host 
cell through late endosomes entering the nucleoplasmic reticulum 
(Figure 1A).23 Therein, EV‐associated cargo molecules can modify 
the gene expression of the host cells. These surprising findings are 
in line with numerous studies showing the atypical nuclear localiza‐
tion of the EV‐associated proteins CD9 and CD133 as well as the 
shuttling of proteins and nucleic acids to nucleoplasm of recipient 
cells.3,24‐28 Recently, we described that two proteins, ie vesicle‐as‐
sociated membrane protein‐associated protein A (VAP‐A) and the 
cytoplasmic oxysterol‐binding protein‐related protein 3 (ORP3), 
are essential for the entry and the tethering of late endosomes to 
nuclear envelope invaginations of type II (Figure 1B). They form a 
tripartite complex with late endosome‐associated Rab7 proteins.29 
Silencing VAP‐A or ORP3 abrogated the association of Rab7‐posi‐
tive late endosomes with nuclear envelope invaginations, hence the 
transport of internalized EV‐derived cargo molecules to the nucle‐
oplasm of recipient cells.29 The nuclear pores play a role in these 
processes given the treatment with importazole, a small molecule in‐
hibitor of importin‐β‐mediated nuclear import, impaired the nuclear 
transfer of EV‐derived proteins.23 Finally, the initial internalization 
of CD9+ EVs occurs by endocytosis, which is an essential step for 
the nuclear localization of EV‐associated materials, given dynasore 
and methyl‐β‐cyclodextrin, two compounds known to inhibit the en‐
docytosis mediated by clathrin/dynamin and lipid raft respectively, 
abrogated it.23
CD9 (alias Tetraspanin‐29, motility‐related protein‐1) is an inte‐
gral membrane protein that is physiologically involved in cell fusion, 
adhesion and motility.30‐32 For instance, CD9 has an important role 
in muscle cell fusion and in canine distemper virus and HIV‐1‐induced 
cell‐cell fusion.33‐35 Depending on the context, CD9 functions have 
a metastasis suppressor or promoter activity (reviewed in Ref.36). 
CD9 has been extensively studied as a potential therapeutic target. 
Anti‐CD9 monoclonal antibodies (Ab) were found to specifically in‐
hibit the trans‐endothelial migration of melanoma cells.37 We have 
shown that anti‐CD9, but not anti‐CD133, Ab enhances the nuclear 
uptake of EVs in recipient cells (Figure 1C).23 This effect is greater in 
melanoma cells than in mesenchymal stromal cells (MSCs), presum‐
ably because of the higher expression level of CD9 in cancer cells in 
comparison to stromal cells. Moreover, silencing CD9 in EVs and/or 
recipient cells strongly decreased the endocytosis of EVs and abol‐
ished the nuclear transfer of their contents, even in the presence of 
the anti‐CD9 Ab (Figure 1C).23
Here, we designed a strategy to block the uptake of EVs and 
the nuclear translocation of their cargos by recipient cells. To that 
aim, we generated an antigen‐binding fragment (Fab fragment; 
hereafter CD9 Fab) from 5H9 anti‐CD9 Ab (CD9 Ab), which could 
potentially saturate CD9 molecules present at the cell surface of 
host cells and EV‐associated ones and hence impair their func‐
tion.38 The Ab and Fab fragment derived therefrom have been 
successfully employed for the treatment of different types of 
cancer, mainly through the inhibition of cell surface receptors.39 
We report that monovalent CD9 Fab at doses achievable in vivo40 
impedes the uptake of EVs in different melanoma cell lines and 
primary MSCs and consequently inhibits the nuclear transfer of 
their cargo proteins. Combined with other approaches, notably 
the direct targeting of cancer cells, such setting could lead to a 
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new modality in cancer treatment by inhibiting the intercellular 
communication within the cancer cell niche.
2  | METHODS
2.1 | Cell culture
The FEMX‐I cell line was originally derived from the lymph node me‐
tastasis of a patient with malignant melanoma.41 FEMX‐I cells were 
highly metastatic in immunodeficient mice.41,42 They were found to be 
wild‐type for BRAF, PTEN and NRAS.23,29 The human A375 melanoma 
cell line was obtained from the American Type Culture Collection (cat‐
alog number #CRL‐1619™), whereas the human C8161 melanoma cell 
line was obtained from G. Pizzorno (University of Tennessee College 
of Medicine, Chattanooga, TN).43,44 All cell lines were cultured in 
RPMI‐1640 (#10‐041‐CV; Corning Inc., Corning, NY) containing 10% 
foetal bovine serum (FBS; Atlanta Biologicals Inc., Flowery Branch, 
GA), 2 mmol/L l‐glutamine, 100 U/mL penicillin and 100 μg/mL strep‐
tomycin (Corning Inc.). Cells were used between passages 3 and 15. 
Cell lines were authenticated by morphology, proteomics and gene 
expression analysis as described.45 They were regularly tested for my‐
coplasma contamination using Venor™ GeM mycoplasma detection kit 
(Sigma‐Aldrich, St. Louis, MO).
Human bone marrow‐derived MSCs, isolated from bone marrow 
aspirates from normal adult donors after obtaining informed consent 
as described,46 were obtained from Dr. D. J. Prockop (Texas A&M) and 
prepared under a protocol approved by the Texas A&M Institutional 
Review Board. MSCs were used between passages 2 and 5. Their 
multipotency was regularly monitored by their differentiation into 
adipocytes and osteoblasts.47 MSCs and FEMX‐I cells expressing ec‐
topically CD9‐green fluorescent protein (GFP) fusion protein were 
established as described.23 Under these conditions, almost all cells 
are positive. They were used to produce fluorescent EVs (see below). 
FEMX‐I cells depleted of CD9 by means of CD9 shRNA lentiviral par‐
ticles were previously described.23 Approximately 85% of infected 
cells showed no CD9 expression (data not shown).
2.2 | Production of CD9 antibody Fab fragment
Culture of 5H9 hybridoma cells38 and the production of CD9 Ab were 
performed at Mayo Clinic (Antibody Hybridoma Core, Rochester, MN). 
Conditioned media from hybridoma cultures growing in roller bottles in 
IMDM media (#12440‐053, Thermo Fisher Scientific, Gibco, Waltham, 
MA) containing 10% premium FBS (#S11150, Atlanta Biologicals Inc., 
Flowery Branch, GA) was pelleted in 250 mL centrifuge tubes at 1600 g 
The supernatant was clarified through 0.45‐μm Nalgene filters to re‐
move remaining cell debris. The clarified supernatant was then passed 
through and bound to Protein G Sepharose FF HiLoad™ 26/40 columns 
(GE Healthcare, Pittsburgh, PA). Bound antibody was eluted with 
100 mmol/L glycine buffer, pH 2.7. Eluted Ab was then immediately 
neutralized with 1 mol/L Tris‐HCl, pH 9 and desalted with HiPrep 
26/10 columns (GE Healthcare). The buffer was exchanged with 1X 
PBS and the protein concentration was determined by measuring 
absorbance at 280 nm. Aliquots of the antibody (1 mg/mL) were stored 
at −80°C without addition of sodium azide.
The Fab fragment was generated using the Pierce Fab Purification 
kit (#44985; Thermo Fisher Scientific). Briefly, the CD9 Ab (500 μg) 
was incubated with papain immobilized on agarose resin for 3 hours at 
37°C. The digested antibody was collected by centrifugation (5000 g, 
1 minute) using a spin column and the flow through containing the an‐
tibody was placed in a new tube. The column was then washed once 
with PBS to recover any remaining antibody, which was pooled with 
the flow through. The fragment crystalline (Fc) fragment was then re‐
moved from digested antibody samples using NAb Protein A Plus Spin 
Column. After 10 minutes of centrifugation (1000 g), the Fab fragment 
found in the flow through was collected. The column was then washed 
twice with PBS. Each washing fraction was pooled with the Fab frac‐
tion. Antibody was concentrated using Microsep™ Advance Centrifugal 
Devices (10K molecular weight cut‐off; Pall Corporation). The final 
concentration of CD9 Fab was 0.75‐0.85 mg/mL. The Fab preparation 
was assessed using sodium dodecyl sulphate‐polyacrylamide gel elec‐
trophoresis (SDS‐PAGE) and Coomassie blue staining (see below).
2.3 | SDS‐PAGE and immunoblotting
Preparation of Fab fragments was assessed using SDS‐PAGE under 
non‐reduced or reduced (ie in the presence of β‐mercaptoetha‐
nol) conditions. Samples were run on a 4%‐12% Bis‐Tris precast 
gel (Thermo Fisher Scientific, Life Technologies) and stained with 
Coomassie blue (Teknova, Hollister, CA) for 10 minutes. The gel was 
destained with 40% methanol/10% acetic acid solution.
Cells were solubilized in lysis buffer (1% Triton X‐100, 
100 mmol/L NaCl, 50 mmol/L Tris‐HCl, pH 7.5) supplemented with 
the Set III protease inhibitor cocktail (Calbiochem, Burlington, MA) 
for 30 minutes on ice. Cell lysates were centrifuged at 12 000 g 
for 10 minutes in 4°C. The supernatant was collected and Laemmli 
sample buffer without reducing agent was added. Proteins were 
separated using either 12% SDS‐PAGE gel (Figure 2 and Figure 
S1) or a precast gel (see above; Figure S3) along with the Trident 
prestained protein molecular weight ladder (GeneTex, Irvine, CA) 
and transferred overnight at 4°C to a nitrocellulose membrane 
(Thermo Fisher Scientific) or poly(vinylidene difluoride) mem‐
brane (Millipore, Bedford, MA: pore size 0.45 μm). After transfer, 
membranes were incubated in a blocking buffer (PBS contain‐
ing 1% bovine serum albumin [BSA] or 5% low fat milk powder 
and 0.3% Tween 20) for 60 minutes at room temperature (RT). 
Afterward, the membranes were probed using either primary 
CD9 Fab (1 μg/mL) generated from mouse 5H9 Ab (see above) 
or commercial mouse anti‐CD9 (clone P1/33/2, #sc‐20048; 
Santa Cruz Biotechnology, Santa Cruz, CA) or anti‐β‐actin (clone 
C4, #sc‐47778; Santa Cruz Biotechnology) Ab for 60 minutes at 
RT. After three washing steps of 10 minutes each with PBS con‐
taining 0.1% Tween 20, the antigen‐antibody complexes were 
detected using two protocols. In the case of CD9 Fab, we used 
goat anti‐mouse Fab specific horseradish peroxidase (HRP)‐con‐
jugated secondary antibody (#A2304; Sigma‐Aldrich), which was 
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visualized with enhanced chemiluminescence reagents (ECL sys‐
tem; Amersham Corp., Arlington Heights, IL). The membranes 
were exposed to films (Hyperfilm ECL; Amersham‐Pharmacia). 
With other Abs, the IRDye 680RD anti‐mouse IgG (#926‐68070; 
LI‐COR Biosciences, Lincoln, NE) was applied. Membranes were 
washed thrice (10 minutes each) in PBS containing 0.1% Tween 20, 
rinsed in ddH2O and antigen‐antibody complexes were visualized 
using an Odyssey CLx system (LI‐COR).
2.4 | Production of CD9‐GFP+ EVs
Extracellular vesicles were enriched by differential centrifugation 
from 72 hour‐conditioned media (serum‐free Dulbecco's modified 
eagle medium [DMEM]/Ham's F‐12 1:1, supplemented with 2% B‐27 
[Thermo Fisher Scientific]) of engineered FEMX‐I cells and MSCs 
expressing CD9‐GFP as described previously.21,22 Conditioned me‐
dium was centrifuged at 10 000 g for 30 minutes at 4°C and the re‐
sulting supernatant was centrifuged at 200 000 g for 60 minutes at 
4°C. The pellet was re‐suspended in 200 μL of PBS. To determine 
the EV concentration, we used the light‐scattering characteristics 
of 488‐nm laser light on EV preparations undergoing Brownian 
motion injected by continuous flow into the sample chamber of a 
Nanosight LM10 unit (Malvern Panalytical Inc., Westborough, MA). 
The calculated EV concentration was an average of six 30‐second 
video recordings. As described previously, the average size of EVs 
produced by FEMX‐I cells and MSCs was 123 and 114 nm respec‐
tively.23 Those produced by FEMX‐I cells were formerly character‐
ized by electron microscopy.21
2.5 | Incubation of cells with EVs
Cells (1 × 105) were plated into 35‐mm microscopy dishes containing 
0.17‐mm thick glass coverslips on the bottom and incubated over‐
night at 37°C to allow complete cell adherence (MatTek Corporation, 
Ashland, MA). Afterward, they were incubated with various concen‐
trations of CD9‐GFP+ EVs (eg, 5 × 107 particles per mL [0.075 μg pro‐
tein per mL]; 2.5 × 108 particles per mL [0.375 μg protein per mL] or 
1 × 109 particles per mL [1.5 μg protein per mL]) for 5 hours at 37°C 
prior to fixation. EVs were derived from the same cell type as used 
for the recipients except for A375 and C8161 cells in which EVs were 
produced from CD9‐GFP transfected FEMX‐I cells. In some experi‐
ments, EVs and/or cells were pre‐incubated with CD9 Fab or CD9 Ab 
at various concentrations as indicated for 30 minutes at 4 and 37°C 
respectively. The EVs and cells were then incubated together in the 
presence of antibodies (or without as control) for 5 hours at 37°C 
prior to analysis.
2.6 | Confocal laser scanning microscopy and 
fluorescence quantification
Cell surface immunolabelling of native or CD9‐depleted FEMX‐I 
cells was performed as described.48 Briefly, cells growing on fi‐
bronectin‐coated coverslips were washed with ice‐cold PBS con‐
taining 1 mmol/L CaCl2 and 0.5 mmol/L MgCl2 (Ca/Mg‐PBS) and 
incubated in blocking buffer I (Ca/Mg‐PBS containing 0.2% gela‐
tin) for 10 minutes. Cells were then incubated for 30 minutes with 
CD9 Fab or CD9 Ab at different concentrations (eg, 5, 10, 25 and 
50 μg/mL) diluted in blocking buffer. The whole procedure was 
performed at 4°C. Afterward, they were fixed in 4% paraformalde‐
hyde (PFA) for 30 minutes at RT, quenched with 50 mmol/L NH4Cl 
for 10 minutes, washed in PBS and incubated in blocking buffer II 
(PBS containing 0.2% gelatin) for 20 minutes. Samples were incu‐
bated with fluorescein isothiocyanate (FITC)‐conjugated secondary 
antibody specific either for the mouse Fab or Fc fragment (#F4018, 
#F5387 respectively, 1:200; Sigma‐Aldrich) diluted in blocking 
buffer II. Nuclei were labelled with 4′‐6‐diamidino‐2‐phenylindole 
(1 μg/mL; Sigma‐Aldrich). Cells were washed with PBS and distilled 
water then mounted in Mowiol 4.88 (Merck, Darmstadt, Germany). 
Images were captured with Leica SP5 upright confocal microscope 
under the same settings for both Fab‐ and Fc‐specific secondary 
antibody labelling. Composites of 27‐30 optical sections are shown 
(Figure 2A,B). The images were prepared using Fiji49 and Adobe 
Illustrator software.
Alternatively, cells incubated with CD9‐GFP+ EVs (see above) 
were fixed in 4% PFA and afterward permeabilized with 0.2% 
Tween 20 diluted in PBS (permeabilization buffer). Both steps 
F I G U R E  1   Entry and delivery of extracellular vesicles (EV)‐derived cargo molecules into the nucleoplasm of recipient cells. A, Two 
major steps were proposed to explain the delivery of EV‐associated molecules to the nuclear compartment of recipient cells. First, the 
EVs are internalized by endocytosis at the plasma membrane (i). Second, once inside the endocytic pathway, a fraction of late endosomes 
(LE) penetrates the type II nuclear envelope invaginations where their content, notably the endocytosed EV‐associated molecules, are 
transferred into the nucleoplasm (ii). Two types of nuclear envelope invaginations are described. Type I invaginations (I) are those in which 
solely the inner nuclear membrane (INM) penetrates into the nucleoplasm, whereas type II invaginations (II) involve both the outer nuclear 
membrane (ONM) and INM. The endoplasmic reticulum (ER) is a continuation of ONM. B, Key players involved in the translocation of Rab7+ 
late endosomes to nuclear envelope invagination. Two proteins, vesicle‐associated membrane protein‐associated protein A (VAP‐A) and the 
cytoplasmic oxysterol‐binding protein‐related protein 3 (ORP3) forming a tripartite complex with late endosome‐associated Rab7 protein, 
are indispensable for the entry of late endosomes to the nuclear envelope invagination and/or their tether to ONM (I). Nuclear pores are 
somehow involved in the translocation of EV‐associated soluble (II) and membranous (III) cargo molecules into the nucleus. It remains to 
be explained how membranous components of EVs are extracted from the late endosomal membrane upon fusion of the former with 
the latter and the transport mechanism through nuclear pores, which are size restricted. C, Silencing CD9 in recipient cells and/or EVs or 
both interferes with the endocytosis of EVs and the nuclear transfer of their cargo molecules. Although the presence of divalent CD9 Ab 
stimulated these events with native cells and EVs, the lack of CD9 abrogated them.23 Panels A and B were modified from Ref.29
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were performed for 15 minutes at RT. They were then incubated in 
blocking buffer III (PBS containing 1% BSA) and labelled with mouse 
anti‐SUN2 Ab (clone A‐10, #sc‐515330; Santa Cruz Biotechnology) 
for 60 minutes each step at RT. Cells were washed twice with 
PBS, incubated with tetramethylrhodamine (TRITC)‐conjugated 
anti‐mouse IgG (#715‐025‐150; Jackson ImmunoResearch, West 
Grove, PA) or Cy5‐conjugated anti‐mouse IgG (#715‐175‐150; 
Jackson ImmunoResearch) secondary antibodies for 30 minutes 
and again washed twice prior to observation. All antibodies were 
diluted in permeabilization buffer containing 1% BSA. Cells were 
imaged in PBS using confocal laser scanning microscopy (CLSM) 
using a Nikon A1R+ inverted confocal microscope with a 60X Apo‐
TIRF oil‐immersion objective and a numerical aperture of 1.49 at 
either 512 × 512 or 1024 × 1024 pixel resolution. Solid‐state la‐
sers of 488, 561 and 638 nm solid‐state lasers were used to excite 
GFP, TRITC and Cy5 respectively and corresponding fluorescence 
emissions were collected using 500‐550, 570‐620 and 662‐737 nm 
long pass filters.
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All images were acquired under the same microscope settings 
for subsequent calculations of mean fluorescence intensity and 
recorded using NIS Elements software (Nikon). Raw images were 
processed using Fiji. Each optical section through the cell (21 sec‐
tions of 0.4 μm for cancer cells and 0.2 μm for MSCs) was assessed 
individually. Any observed GFP fluorescent signal was counted as 
EV‐derived biomaterials and data collectively calculated. To count 
nuclear fluorescent materials, a region of interest (ROI) was drawn 
along the nucleus on each optical section and an auto threshold 
generated by Fiji was applied. Positive signals were counted using 
the “analyze particle” function. To determine the value of cyto‐
plasmic GFP fluorescence for each cell, an ROI was also drawn 
around the cytoplasm, using the cell border as a guide, but exclud‐
ing the nucleus.
2.7 | Flow cytometry
FEMX‐I cells were trypsinized using 0.05% trypsin with 0.53 mmol/L 
EDTA (Corning Inc.), washed twice in PBS and re‐suspended in PBS 
containing 1% BSA. Cell suspension aliquots of 100 μL (1 × 106 
cells) were incubated with either CD9 Fab or CD9 Ab (clone 5H9) 
(both at 10 μg/mL in PBS containing 1% BSA) for 30 minutes at 4°C. 
After two washing steps with PBS, samples were incubated with 
FITC‐conjugated secondary antibody specific either for the mouse 
Fab or Fc fragment (see above, 1:600) for another 30 minutes at 
4°C. As negative controls, primary Ab was omitted. For competi‐
tive inhibition experiment, cells were incubated first with CD9 Fab 
at different concentrations (0, 5, 10, 25 and 50 μg/mL) and then 
with CD9 Ab (10 μg/mL) followed by Fc‐specific FITC‐conjugated 
secondary antibodies. All incubations were performed for 30 min‐
utes at 4°C. To set up the background staining reminiscent of a 
residual undigested CD9 Ab in CD9 Fab preparation, we omitted 
CD9 Ab. After washing with PBS, 20 000 events were acquired on 
a LSRII flow cytometer (BD Biosciences). Instrument settings and 
gating strategies were established using cells incubated solely with 
individual secondary antibody as negative controls. Data were 
analysed using FlowJo software (TreeStar, Ashland, USA). Median 
fluorescence intensity (MFI) was calculated as a difference of MFI 
values of stained and negative control populations.
F I G U R E  2   Characterization of CD9 Fab. A, Cell surface 
immunofluorescence on native FEMX‐I cells. FEMX‐I cells 
were surface labelled in the cold with CD9 Fab at different 
concentrations as indicated (μg/mL), PFA‐fixed and incubated 
with either anti‐Fab (top panels) or anti‐Fc (bottom panels) 
specific secondary conjugated to a fluorochrome (green). Nuclei 
were counterstained with 4′‐6‐diamidino‐2‐phenylindole (DAPI). 
B, Cell surface immunofluorescence on CD9‐depleted FEMX‐I 
cells. Native FEMX‐I cells and CD9 shRNA‐transduced cells were 
surface‐labelled in the cold with CD9 Fab (top panels) or CD9 Ab 
(bottom panels) at different concentrations (μg/mL), as indicated, 
PFA‐fixed and incubated with anti‐Fab or anti‐Fc specific secondary 
conjugated to a fluorochrome (green) respectively, prior to 
DAPI staining. Note that under these conditions, about 15% of 
infected cells still express CD9 in a proportion similar to native 
cells (asterisks). Scale bar, 25 μm. C, Immunoblotting. Detergent 
cell lysate (100‐μg protein) prepared from melanoma FEMX‐I 
cells was probed using Fab CD9 and horseradish peroxidase‐
coupled anti‐Fab specific secondary antibody. β‐actin was used 
as control. Position of prestained molecular weight markers (kDa) 
are indicated. Bracket, CD9 immunoreactivity. D, Flow cytometry. 
FEMX‐I cells were surface labelled with either CD9 Fab (10 μg/
mL, top) or CD9 Ab (10 μg/mL, bottom) followed by fluorochrome‐
conjugated anti‐Fab or anti‐Fc specific secondary antibody 
respectively. E, CD9 Fab inhibits the cell binding of native CD9 Ab. 
FEMX‐I cells were sequentially labelled with CD9 Fab at different 
concentrations as indicated (μg/mL) followed by CD9 Ab (10 μg/
mL) and fluorochrome‐conjugated anti‐Fc specific secondary 
antibody. Samples were analysed using flow cytometry. The 
median fluorescence intensity (MFI) is indicated. As negative and 
background controls, primary Ab (D) or CD9 Ab (E) was omitted
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To determine the amount of cell surface CD9 molecules in a given 
cell, Quantum™ Simply Cellular® anti‐mouse IgG kit (#815; Bangs 
Laboratories Inc., Fishers, IN) was utilized. Cells (1 × 105) and 4 mi‐
crosphere populations, containing increasing levels of Fc‐specific 
capture antibody, were incubated with phycoerythrin‐conjugated 
anti‐CD9 Ab (clone M‐L13, #555372; BD Biosciences, San Jose, CA) 
in PBS containing 0.5% BSA for 30 minutes on ice. Both cells and 
microspheres were then analysed using flow cytometry using the 
same settings as above according to manufacturer's instructions. A 
standard curve was generated using the median channel values of 
the microspheres and the amount of CD9 molecules per cell was de‐
termined from this curve. All calculations were performed with the 
QuickCal analysis program provided in the kit.
2.8 | Statistical analysis
All experiments were performed at least in triplicate. A minimum 
of 30 cells was analysed in each experiment. Error bars in graphical 
data represent means ± standard deviation. Statistical analysis was 
determined by one‐way analysis of variance followed by pairwise 
comparison of means with Dunnett's multiple comparison adjust‐
ment using the statistical program Stata 12 (StataCorp LLC, College 
Station, TX). P‐values inferior to 0.05 were considered significant.
3  | RESULTS
3.1 | Generation of CD9 antibody Fab fragment
Given the positive impact of divalent Ab directed against CD9 
on the uptake of CD9+ EVs by melanoma cells and the negative 
impact upon silencing CD9 on either EVs or recipient cells,23 we 
sought whether CD9 Fab could influence the internalization and 
consequently the intercellular transfer of EV‐associated cargo 
molecules. To investigate this issue, we generated CD9 Fab from 
5H9 Ab, which recognizes an unidentified epitope in the extracel‐
lular part of CD9 (Figure S1A).38 The Ab (IgG1 kappa) produced 
from hybridoma clone 5H9 was digested with papain to generate 
the Fab and Fc fragments. The latter were removed selectively 
using immobilized protein A (Figure S1B). As observed using SDS‐
PAGE under non‐reducing and reducing conditions, the 5H9 Ab 
was successfully digested and the 50‐kDa CD9 Fab was isolated 
(Figure S1C).
3.2 | Characterization of CD9 Fab
To determine the functionality of CD9 Fab, we evaluated its bind‐
ing to melanoma FEMX‐I cells by various methods. First, cells 
growing on fibronectin‐coated support were surface labelled in 
the cold with CD9 Fab at different concentrations followed by a 
fluorochrome‐conjugated secondary antibody specific either for 
the mouse Fab or Fc fragment. The CLSM analysis revealed that 
the antigen‐CD9 Fab complex is recognized by anti‐Fab secondary 
antibody already at low concentration of primary Ab (Figure 2A, 
top panels). In contrast, solely a very weak labelling was detected 
with a secondary antibody directed against mouse Fc, indicat‐
ing the effective papain digestion of CD9 Ab (Figure 2A, bottom 
panels). When a similar experiment was performed with CD9‐de‐
pleted FEMX‐I cells,23 almost no immunolabelling was detected 
either with CD9 Fab or full‐length antibody (Figure 2B, top and 
bottom panels respectively). Second, we analysed whether CD9 
Fab can recognize CD9 by immunoblotting. To that end, deter‐
gent lysate prepared from FEMX‐I cells was resolved on SDS‐
PAGE under non‐denaturing condition and probed with CD9 Fab. 
As shown in Figure 2C, CD9 Fab recognized the CD9 molecules. 
Third, we evaluated the capacity of CD9 Fab to detect its antigen 
using flow cytometry. A suspension of FEMX‐I cells was subjected 
to immunolabelling in the cold using either CD9 Fab or full CD9 
Ab followed by fluorochrome‐conjugated secondary antibody 
specific either for mouse Fab or Fc fragment respectively. As 
negative control, primary antibody was omitted. Flow cytometry 
analyses indicated that CD9 Fab could detect CD9+ cells similar to 
the native anti‐CD9 Ab (Figure 2D). Altogether, these experiments 
demonstrated that CD9 Fab recognizes its antigen under various 
conditions, notably its native conformation.
3.3 | CD9 Fab interferes with the cell binding of 
native CD9 antibody
Can CD9 Fab interfere with the binding of corresponding native CD9 
Ab? To address this issue, we pre‐incubated FEMX‐I cells in suspen‐
sion with various concentrations of CD9 Fab prior to the addition of 
CD9 Ab and fluorochrome‐conjugated secondary antibody specific 
for the Fc fragment. Samples were analysed by flow cytometry. As a 
positive control, CD9 Fab was omitted whereas CD9 Ab was absent 
for the background control. As shown in Figure 2E, CD9 Fab blocked 
the binding of the native Ab in a dose‐dependent fashion, indicating 
that it could specifically label the cell surface CD9 molecules. We 
concluded that the monovalent CD9 Fab could be useful in achieving 
our objective, ie interfering with the uptake of CD9+ EVs.
3.4 | Differential effect of CD9 Fab versus native 
antibody on the internalization of EVs
To determine the impact of CD9 Fab on the internalization of EVs 
by melanoma cells, we used engineered FEMX‐I cells to express the 
CD9‐GFP fusion protein.23 These cells release in vivo‐labelled fluo‐
rescent EVs that could be used to monitor EV uptake upon incuba‐
tion with recipient cells. CD9‐GFP+ EVs released in the conditioned 
culture media were enriched by differential centrifugation (for details 
see Methods,23). Prior to the exposure of native FEMX‐I cells to CD9‐
GFP+ EVs, cells were pre‐incubated for 30 minutes at 37°C with either 
CD9 Fab or CD9 Ab (25 μg/mL). As control, no antibody was added. 
Afterward, cells were incubated with CD9‐GFP+ EVs (2.5 × 108 parti‐
cle per mL) without removing the antibodies for 5 hours and then fixed, 
immunolabelled for protein SUN domain‐containing protein 2 (SUN2), 
an inner nuclear membrane protein and analysed using CLSM. At first 
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glance, we noticed that the uptake of CD9‐GFP+ EVs by recipient cells 
seemed variable under the native conditions, ie without the addition 
of CD9 Ab. Therein, GFP fluorescence appears as strong, medium or 
weak among cells (Figure S2A). In contrast, GFP fluorescence becomes 
more homogeneous within the cell population upon the addition of 
antibodies. A three‐dimensional reconstruction of labelled recipient 
cell revealed that CD9‐GFP signal associated with their cytoplasm 
was considerably reduced in the presence of CD9 Fab by compari‐
son to control (Figure 3A, uncut)—for an overview see Figure S2A. 
Quantification of each optical section confirmed it (Figure 3B). In 
contrast, the presence of CD9 Ab yielded the opposite effect, ie, an 
increase of cytoplasmic CD9‐GFP was detected (Figure 3A, uncut; 
3B). Interestingly, similar outcome were observed with two other 
melanoma cell lines, A375 and C8161, exposed to FEMX‐I cell‐derived 
F I G U R E  3   CD9 Fab impedes the uptake of extracellular vesicles (EVs) and nuclear transfer of their cargo proteins in melanoma and 
stromal cells. A‐C, FEMX‐I cells were pre‐incubated (30 min) without (control) or with CD9 Fab or CD9 Ab (25 μg/mL) prior to the exposure 
to fluorescent EVs derived from CD9‐GFP+ FEMX‐I cells for 5 h. Different concentrations of EVs were used (A‐C, 2.5 × 108 particle per mL 
[blue]; C, 5.0 × 107 [red] or 1.0 × 109 particle per mL [green]). Samples were then fixed and immunolabelled for SUN2 prior to confocal laser 
scanning microscopy. A three‐dimensional reconstruction of the entire cell (uncut) or three sections (0.4‐μm slices each, section) is shown 
(A). CD9‐GFP appears as discrete punctate signals either in the cytoplasm or nucleoplasm (circles) of recipient cells. The amount of CD9‐GFP 
signal was quantified using serial optical sections through a cell using the cytoplasmic (B) and nuclear (C) compartments as a region of 
interest (see Figure S2B). Mean with the range of fluorescence per slice from 10 individual cells are shown (B). D, Native MSCs were exposed 
to EVs (1.0 × 109 particle per mL) derived from CD9‐GFP+ MSCs upon their pre‐incubation without or with CD9 Fab or CD9 Ab as described 
above. Punctate nuclear CD9‐GFP signal per cell was quantified. Means ± SD are shown (C, D). 50 (C) or 20 (D) cells were evaluated per 
experiment (n = 3). P‐values are indicated. N.S., not significant. Scale bars, 5 μm
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CD9‐GFP+ EVs (Figure 4A), indicating that CD9 Fab inhibits the uptake 
of EVs.
3.5 | CD9 Fab inhibits the nuclear transfer of EV‐
derived cargo proteins
We previously reported that cargo proteins derived from EVs are 
not only internalized by host cells, but also a fraction of them is 
transferred to their nucleoplasm by the intermediate of late en‐
dosomes entering into nucleoplasmic reticulum.23,29 Does CD9 
Fab interfere with this mechanism? The analysis of the nuclear 
compartment of melanoma cells pre‐treated with monovalent or 
divalent Abs prior to incubation with CD9‐GFP+ EVs (2.5 × 108 par‐
ticle per mL) showed a decrease or an increase in the CD9‐GFP+ 
signals in the nucleoplasm respectively, compared to the control 
(Figure 3A, section, green circle; 3C; see also Table 1). As previ‐
ously demonstrated,23,29 CD9‐GFP+ signal in the nuclear compart‐
ment appeared with a punctate pattern (Figure 3A; Figure S2B, 
green circle).
The addition of different amounts of CD9‐GFP+ EVs (eg, 5.0 × 107 
or 1.0 × 109 particle per mL) was also evaluated in FEMX‐I cells. In most 
cases, the numbers of nuclear CD9‐GFP were significantly lower or 
higher in cells exposed to CD9 Fab or CD9 Ab respectively (Figure 3C). 
Only with a high amount of EVs (ie 1.0 × 109 particle per mL) no 
F I G U R E  4   CD9 Fab impedes the 
uptake of extracellular vesicles (EVs) 
and nuclear transfer of their cargo 
proteins in various malignant melanoma 
cells. (A‐C) Melanoma A375 or C8161 
cells were incubated (30 min) without 
(control) or with CD9 Fab or CD9 Ab 
(25 μg/mL) prior to the exposure to 
fluorescent EVs (2.5 × 108 particle per 
mL) derived from FEMX‐I cells expressing 
CD9‐GFP for 5 h. Samples were then 
fixed and immunolabelled for SUN2 prior 
to confocal laser scanning microscopy. 
Cytoplasmic (A) and nuclear (B, C) 
CD9‐GFP signals per cell were quantified 
using Fiji. Means with the range of 
fluorescence per slice from 10 individual 
and representative cells are shown (A). 
30 cells were evaluated per condition and 
experiment (B) and the means ± SD of 
three independent experiments are shown 
(C). P‐values are indicated
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significant difference was observed between CD9 Ab and control. Similar 
observations were made with A375 and C8161 cells (Figure 4B,C).
When the same experiments were performed with primary 
MSCs as recipient cells as well as donor cells for fluorescent EVs 
(1 × 109 particle per mL), we observed also a significant decrease 
in nuclear and cytoplasmic CD9‐GFP in cells pre‐treated with CD9 
Fab (25 μg/mL) (Figure 3D; data not shown). The CD9 Ab did not 
significantly increase the EV uptake which can be explained by a lim‐
ited quantity of CD9 molecules in MSCs in comparison to melanoma 
cells, as observed by immunoblotting and quantitative fluorescence 
analyses using flow cytometry (Figure S3A‐C).
3.6 | A minimal concentration of CD9 Fab is 
necessary to interfere with EV uptake
We assessed whether the uptake of EVs is dependent on the con‐
centration of CD9 Fab. FEMX‐I cells were subjected to increasing 
concentrations of CD9 Fab or CD9 Ab prior to incubation with CD9‐
GFP+ EVs (2.5 × 108 particle per mL). As shown in Figure 5A, the up‐
take of EVs was progressively inhibited as the concentration of CD9 
Fab increased, whereas the opposite effect was again observed in 
cells treated with CD9 Ab, ie more EVs were internalized with in‐
creasing CD9 Ab concentration. A similar trend was observed in the 
number of CD9‐GFP signals in the nuclear compartment (Figure 5B). 
These results are in line with the interference of CD9 Fab to cell 
surface CD9 Ab binding observed using flow cytometry (Figure 2E). 
Thus, a minimal amount of antibody (ie 25 μg/mL) seems to be indis‐
pensable to inhibit (or promote) the EV uptake.
Lastly, we determined whether the pre‐incubation of EVs with 











Controlb  A 8.42 ± 0.74 —
B 8.41 ± 0.61 —
C 8.02 ± 0.44 —
CD9 Fab A 2.89 ± 0.13 0.05
B 2.99 ± 0.45 0.001
C 1.53 ± 0.09 0.0001 0.05
CD9 Ab A 15.67 ± 1.20 0.005
B 14.17 ± 0.76 0.001
C 14.20 ± 0.32 0.0001 0.5
aA, Cells were pre‐incubated with antibody (25 μg/mL, 30 min, 37°C) before the addition of 
CD9‐GFP+EVs (5 h). B, CD9‐GFP+EVs were pre‐incubated with antibody (25 μg/mL, 30 min, 4°C) 
before their incubation with cells (5 h). C, Cells and CD9‐GFP+EVs were pre‐incubated with 
antibody (12.5 μg/mL each, 30 min, 37 or 4°C respectively) before their co‐culture (5 h). 
bControl refers to the three experimental procedures (A‐C) without the addition of antibody. 
cAt least 30 cells were evaluated per condition (n = 3). 
TA B L E  1   Differential impact of CD9 
antibody on the nuclear localization of 
extracellular vesicles (EV)‐derived cargo 
protein
F I G U R E  5   Dose‐dependent inhibition of CD9 Fab on the 
extracellular vesicles (EV) uptake and nuclear transfer of their cargo 
proteins. (A, B) FEMX‐I cells were pre‐incubated (30 min) with 
different concentration of CD9 Fab or CD9 Ab as indicated prior to 
the exposure to CD9‐GFP+ EVs (2.5 × 108 particles per mL) for 5 h. 
As control, no antibody was added (–). Cytoplasmic (A) and nuclear 
(B) CD9‐GFP signals per cell were quantified using Fiji. Means ± SD 
are shown. 10 (A) or 30 (B) cells were evaluated per experiment 
(n = 3). They were evaluated in comparison to the control (A, red 
line; B, –). ***, P ≤ 0.001. N.S., not significant
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only as performed until now, influenced internalization and the nu‐
clear localization of EV‐derived cargo proteins. We wanted to rule 
out a potential negative impact of the addition of the Abs (CD9 Fab 
or CD9 Ab) to recipient cells, which could stimulate the internal‐
ization of cell surface CD9, hence limit the EV uptake. If it turned 
out to be the case, all acquired numbers would be underestimated. 
Similarly, we wished to exclude that the addition of Abs, particularly 
CD9 Ab, to EVs would reduce their internalization by favouring, for 
instance, their clustering. As presented in Table 1, we found that the 
pre‐incubation of cells with Abs did not influence the final outcome 
when compared to the pre‐incubation of EVs (procedure A vs. B). 
However, the nuclear localization of EV‐derived cargo proteins was 
significantly reduced when both entities (EVs and cells) were pre‐in‐
cubated individually with the monovalent, but not the divalent, Ab 
(see procedure C by comparison to A).
4  | DISCUSSION
In this study, we demonstrated that a monovalent Ab directed against 
tetraspanin CD9 interferes with the uptake of EVs by cancer cells 
and primary MSCs as well as with the nuclear transfer of their cargo 
proteins. The latter event is probably a direct consequence of the en‐
docytosis inhibition of EVs.23 Under these conditions, CD9 Fab could 
saturate the CD9 molecules located at the surface of cells and EVs 
and consequently interfere negatively with its function (Figure 6A; 
see below). The synergic impact of the pre‐incubation of cells and EVs 
individually with CD9 Fab is consistent with this scenario. Our data 
are in line with an elegant study showing the CD9 Fab can inhibit the 
transfer of materials between CD9‐containing membranous vesicles, 
called epididymosomes and maturing epididymal spermatozoa.50 In 
contrast, divalent CD9 Ab promotes these events, which can be cor‐
related to antibody‐induced cross‐linking of CD9 associated with EVs 
and host cells (Figure 6B). Does CD9 play a role in the initial adhe‐
sion of EVs to the recipient cell? The earlier observation made with 
sperm‐egg fusion suggests it. Jégou and colleagues demonstrated 
that the fertilization process is controlled by sperm‐egg adhesion 
properties driven by CD9.51 In such process, CD9 might organize 
the components (proteins and lipids) of plasma membrane and/or EV 
membrane into a specific tetraspanin web (Figure 6B, green), whose 
constituents (eg, adhesion proteins) would somehow regulate the in‐
teraction with EVs and promote their endocytosis.52‐55 Similarly, CD9 
has been proposed to act as a scaffold in the regulation of adhesion 
molecules at the immune synapse and T lymphocyte activation.56 It 
remains to be determined whether the cis‐dimerization of CD9 in the 
membrane of recipient cells as well as in EVs is involved.57 We could 
not exclude that a trans‐dimerization of CD9, ie molecules expressed 
in opposite membranes, occurs. Indeed, our present data with diva‐
lent Ab as mentioned above and the complete lack of EV endocytosis 
previously observed in melanoma cells in which CD9 was silenced in 
both entities (cells and/or EVs), suggest it (Figure 1C).23 It will be of 
interest to investigate the CD9 cis/trans‐dimerization by co‐immu‐
noprecipitation using engineered CD9 proteins associated with cells 
and EVs with distinct epitope tags.
Besides the exact molecular mechanism regulating the adhesion 
of EVs to recipient cells and their internalization, it will be of interest 
to determine whether other anti‐CD9 antibodies interfere with the 
EV uptake and nuclear transfer of their cargo proteins, as observed 
here with CD9 Fab derived from 5H9 Ab. The proper localization of 
their respective epitope might be crucial to promote these effects 
and it is conceivable that distinct CD9 Fab (or again other CD9 inter‐
acting partners) could potentially synergize their inhibitory effect. 
Other tetraspanin proteins enriched in EVs such as CD81 should also 
be evaluated in this respect.
The intercellular transfer of materials by cancer cell‐produced 
EVs played a significant role in the transformation of microenviron‐
ment, notably in the bone marrow, to favour metastasis and tumour 
growth.7 Interfering locally with these mechanisms, particularly 
the internalization of cancer cell‐derived EVs by MSCs, one of the 
main targeted cellular constituents of tumour niche,58 could find a 
cutting‐edge clinical application. MSCs have an important role in 
co‐ordinating the tumour microenvironment. Transformed MSCs 
produced growth factors favouring tumour growth and angiogene‐
sis, inhibited anti‐tumour immune responses and shaped the tumour 
inflammatory environment.59‐61 Thus, our data with MSCs exposed 
to CD9 Fab might find new avenues to prevent the bone marrow 
transformation. In addition to cancers, other diseases involving the 
intercellular transfer of biomaterials mediated by EVs, such as neuro‐
degenerative diseases (eg, Parkinson's disease, Alzheimer's disease, 
F I G U R E  6   Schematic representation showing the negative 
and positive impact of CD9 Fab and CD9 Ab, respectively, on 
the endocytosis of CD9‐containing extracellular vesicles (EVs). 
(A, B) CD9 Fab will saturate CD9 proteins present at the surface 
of cells and EVs, hence interfere with its CD9 function. CD9 Fab 
can impede the cis/trans‐dimerization of CD9, its oligomerization 
and/or its interaction with other protein partners and block EV 
endocytosis (red bar). In contrast, divalent CD9 Ab could cross‐link 
CD9 proteins associated with host cells and EVs and consequently 
stimulate the endocytosis on EVs (green arrow). In the latter 
case, cis‐dimerization/oligomerization of CD9 might organize the 
components (proteins and lipids) of plasma membrane and/or EV 
membrane into a specific tetraspanin web (green segment), whose 
constituents, notably potential adhesion proteins as illustrated 
would somehow regulate the cell‐EV interaction and promote the 
endocytosis of EVs
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amyotrophic lateral sclerosis), could benefit from this new potential 
therapeutic approach.62,63
Finally, our observations could benefit the areas of regenerative 
medicine and tissue engineering. Here, the stimulation of EV endo‐
cytosis by specific divalent antibodies could favour tissue/organ re‐
pair.64 Myocardial regeneration might be a good example for such 
intervention with MSCs as a promising source of donor cell EVs.65,66 
Such approach could be an interesting alternative to stem cell‐based 
therapy.
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